Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Calypte Biomedical Corporation (CALY) -- Ignore unavailable to you. Want to Upgrade?

To: nysparticus who wrote (377)	8/30/2000 9:24:51 AM
From: DJBEINO	Read Replies (1) \| Respond to of 381

Calypte Biomed Off 21%; CEO Cites Profit-Taking +++++++++ Calypte Biomed Down -2: Volume Is 2.7M Shares Tuesday, August 29, 2000 03:43 PM of DOW JONES NEWSWIRES NEW YORK (Dow Jones)--Calypte Biomedical Corp. (CALY, news, msgs) gave back part of its remarkable run-up of last week, although a company representative said there wasn't any recent news. Shares of the Almeda, Calif., biomedical company were off 20% on heavy volume recently, after sliding 9% Monday. The recent declines followed a tripling in price Friday on news that its HIV-1 test was approved for distribution in China. "If I were to guess, I think it's stabilizing," Chief Executive Nancy Katz said Tuesday. Katz cited profit-taking for recent declines. Calypte, which had traded as high as $4.44 in after-hours trading Friday, slipped recently to $3.13 a share, off 84 cents or more than 21% on Nasdaq volume of 2.7 million shares. Average daily volume is 623,473 shares. The issue hit a 52-week high in March of $7.25 a share. At least one analyst who didn't want to be named on Friday questioned whether market demand in China justified investor enthusiasm for Calypte. But the company has maintained that the product will thrive because of its low cost and the fact that no special training is required to administer the test.